logo
  

Alkermes plc Q1 Earnings Summary

Below are the earnings highlights for Alkermes plc (ALKS):

Earnings: $36.83 million in Q1 vs. -$41.85 million in the same period last year.
EPS: $0.21 in Q1 vs. -$0.25 in the same period last year.
Excluding items, Alkermes plc reported adjusted earnings of $74.06 million or $0.43 per share for the period.

Analysts projected $0.58 per share
Revenue: $350.37 million in Q1 vs. $287.60 million in the same period last year.

For comments and feedback contact: editorial@rttnews.com

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
RELATED NEWS
Follow RTT